Odyssey Therapeutics
ODTX
50 hedge funds and large institutions have $384M invested in Odyssey Therapeutics in 2026 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
42.78% more ownership
Funds ownership: 0% → 42.78% (+43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$66.5M |
| 2 |
LMC
Lightspeed Management Company
Menlo Park,
California
|
+$63.3M |
| 3 |
S
Sanofi
Paris,
France
|
+$34.9M |
| 4 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
+$15.3M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$14.6M |
Top Sellers
ODTX Hedge Fund Activity: Q2 2026 in Review
50 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Odyssey Therapeutics (ODTX) for Q2 2026, worth a combined $384M.
Buyers outnumbered sellers: 50 funds opened new ODTX positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was SR One Capital Management, opening a new position worth an estimated $66.5M.
- 50 institutional investors held Odyssey Therapeutics (ODTX) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $384M of Odyssey Therapeutics stock for Q2 2026.
- 50 funds opened new Odyssey Therapeutics positions in Q2 2026 and 0 closed out, a net change of +50 holders.
- The largest Odyssey Therapeutics buyer in Q2 2026 was SR One Capital Management, an estimated $66.5M added.
Based on aggregated 13F filings for Q2 2026.